OakChart

Pharming Group NV ADR

PHARHealthcare·Biotechnology·Netherlands·Small·NASD·Nov 11 • 3:59 PM ET

13.40+0.18 (1.36%)
2026-11-11 22:51 CET
Market cap
935.69 USD m
Revenue, TTM
386.69 USD m
Net income, TTM
24.04 USD m
Free cash flow, TTM
28.01 USD m
EPS diluted, TTM
0.32
P/E
42.54
Compare

Price

PHAR against its 20, 50 and 200-day averages
2050200miss
10.0012.0014.0016.00109K218KVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26PHARclose 13.4020-day 11.6150-day 10.90200-day 13.5313.4052w low

37.2% under the 52-week high of 21.34 on 27 Jan 2026. 52-week low 9.11 on 19 Oct 2026. Last 15 sessions, 27.8% high to low

Volume 0.53× normal · the line is the 50-bar volume average

Profile

PHAR
52-week range, 35% of the way up
9.1121.34

Pharming Group NV is a holding company, which engages in the development of pharmaceutical products for the treatment of rare diseases and unmet medical needs. The firm offers RUCONEST, which is a recombinant human C1-esterase inhibitor for the treatment of acute hereditary angioedema. It operates through the following segments: RUCONEST, Joenja, Europe, and Rest of the World. The company was founded on November 11, 1988, and is headquartered in Leiden, the Netherlands.

IPODec 23, 2020
Beta-0.08
ATR, 14d0.53
Rel volume0.53
Inst own0.11%

Snapshot

6 groups

Valuation

Index-
Market Cap948.45M
Enterprise Value873.40M
Income24.04M
Sales386.69M
Book/sh4.11
Cash/sh2.68
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees-
IPODec 23, 2020

Ratios

P/E42.54
Forward P/E36.78
PEG0.25
P/S2.45
P/B3.26
P/C5.00
P/FCF33.86
EV/EBITDA18.85
EV/Sales2.26
Quick Ratio2.65
Current Ratio3.23
Debt/Eq0.39
LT Debt/Eq0.36
Option/ShortNo / Yes

Earnings

EPS (ttm)0.32
EPS next Y0.36
EPS next Q0.10
EPS this Y781.00%
EPS next Y3.37%
EPS next 5Y148.88%
EPS past 3/5Y-41.84% -41.23%
Sales past 3/5Y22.40% 12.25%
EPS Y/Y TTM2242.07%
Sales Y/Y TTM6.67%
EPS Q/Q174.95%
Sales Q/Q21.29%
EarningsOct 27 BMO
EPS/Sales Surpr.42.86% 0.00%

Ownership

Insider Own-
Insider Trans-
Inst Own0.11%
Inst Trans14.65%
ROA4.95%
ROE8.65%
ROIC6.06%
Gross Margin82.77%
Oper. Margin8.84%
Profit Margin6.22%
SMA2015.39%
SMA5022.93%
SMA200-0.93%
Trades-

Technical

Shs Outstand70.78M
Shs Float-
Short Float-
Short Ratio1.08
Short Interest0.03M
52W High21.34 -37.21%
52W Low9.11 47.09%
Volatility4.80% 3.76%
ATR (14)0.53
RSI (14)72.71
Beta-0.08
Rel Volume0.53
Avg Volume23.97K
Volume12,722

Performance

Perf Week7.54%
Perf Month41.95%
Perf Quarter8.50%
Perf Half Y3.32%
Perf YTD-24.17%
Perf Year-15.14%
Perf 3Y21.71%
Perf 5Y45.65%
Perf 10Y-
Recom1.00
Target Price30.64
Prev Close13.22
Price13.40
Change %1.36%

Analyst ratings

latest 2 of 2
DateActionAnalystRating changeTargetImplied
Apr 10, 2026InitiatedCCanaccord GenuityBuy$37+176.1%
Dec 09, 2024InitiatedJJefferiesBuy$14+4.5%

Peers

Mkt cap
TickerCompanyMkt cap
PHVSPharvaris NV2.40B
BCRXBiocryst Pharmaceuticals Inc1.97B
NTLAIntellia Therapeutics Inc1.60B
IONSIonis Pharmaceuticals Inc4.72B
ADMAAdma Biologics Inc2.93B
TAKTakeda Pharmaceutical Co ADR66.58B
RAREUltragenyx Pharmaceutical Inc1.70B
MIRMMirum Pharmaceuticals Inc6.18B
ARGXArgen X SE ADR61.48B
KNSAKiniksa Pharmaceuticals International Plc7.52B

News

latest 14 of 100

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-10-270.3000.2100.320117.6117.63
2026Q22026-07-300.0200.0630.02090.2099.523
2026Q12026-05-07-0.0700.001-0.07572.4592.063
2025Q42026-03-120.0700.0150.070106.5111.763
2025Q32025-11-060.1000.0050.10997.3098.222
2025Q22025-07-310.060-0.1050.06893.2082.632
2025Q12025-05-08-0.220-0.025-0.21779.0967.742
2024Q42025-03-130.0500.0190.05492.7081.253
2024Q32024-10-24-0.020-0.003-0.01574.8576.932
2024Q22024-08-01-0.020-0.002-0.01874.1071.942
2024Q12024-05-08-0.1900.007-0.18555.6068.432
2023Q42024-03-14-0.0400.005-0.04181.2071.832
2023Q32023-10-260.005-0.1300.05366.7061.672
2023Q22023-08-030.010-0.0970.02054.9053.233
2023Q12023-05-11-0.170-0.065-0.18742.5050.342
2022Q42023-03-16-0.2050.055-0.22554.6260.252

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY0.6040.5850.602189.12188.74
2020FY0.5780.7680.551223.59220.92
2021FY0.2300.3870.228198.87223.58
2022FY0.1900.4840.194205.62212.01
2023FY-0.1500.020-0.161245.32242.25
2024FY-0.160-0.119-0.176297.2286.4
2025FY0.0400.0310.005376.13387.77
2026FY-0.352--379.53
2027FY-0.364--395.42
2028FY-0.617--401.77
2029FY-0.400--453.79
2030FY-0.560--640.32

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-10-28403107.55104.71110.5
2026Q4S2026-10-27403107.54104.71110.5
2026Q4S2026-10-22403107.34104.71110.2
2026Q4S2026-10-21403111.23104.71120.36
2026Q4S2026-10-14401116.7109.6123.6
2026Q4S2026-10-13401116.7109.6123.64
2026Q4S2026-09-21404116.7109.6123.64
2026Q4S2026-09-17404116.7109.6123.6
2026Q4S2026-07-31403118.43109.6127.28
2026Q4S2026-07-30403118.43109.6127.28
2026Q4S2026-07-21400122.96116.17127.28
2026Q4S2026-06-22330121.52116.17126.2
2026Q4S2026-05-07330121.53116.17126.22
2026Q4S2026-04-09301112.83109.8116.31

Estimate history

EPS, annual-1.7190.4510.6020.5510.2280.194-0.161-0.1760.0380.315
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.0150.054-0.2170.0680.1090.07-0.0750.020.3
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual101.085159.42189.178211.686198.56205.735245.696296.675377.298386.69
Period201720182019202020212022202320242025TTM
Sales, quarterly75.06392.04279.15394.44796.861106.42172.7190.075117.478
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual57.962.1563.13263.88264.87565.63567.10768.03170.16870.778
Period201720182019202020212022202320242025MRQ
Shares, quarterly67.83568.03168.03168.51568.51570.16870.1470.77870.778
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue386.69377.30296.68245.70205.73198.56211.69189.18159.42
Cost of Goods Sold Incl. D&A66.6356.4046.3636.2822.0726.0427.5528.8130.59
Gross Profit320.06320.90250.32209.42183.66172.52184.14160.37128.83
Selling, General and Administrative Excl. Other285.87299.95253.97231.49179.95161.60109.8892.6984.82
Research and Development119.5598.0879.2265.1250.9667.1136.3730.0733.01
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income34.1920.95-3.66-22.073.7110.9274.2667.6844.01
Interest Expense10.4010.959.936.115.476.1810.3113.3416.88
Unusual Expense10.13-7.090.045.861.19-0.113.673.4625.59
Net Income Before Taxes33.0612.26-6.72-11.7416.0822.3543.6351.991.01
Income Taxes10.1510.343.34-1.471.317.076.3311.73-28.47
Consolidated Net Income24.042.55-11.82-10.5613.6815.9737.6640.5129.49
Net Income From Continuing Operations24.042.86-11.82-10.5613.6815.9737.6640.5129.49
Net Income24.042.86-11.82-10.5613.6815.9737.6640.5129.49
EPS (Recurring)0.42-0.03-0.18-0.100.210.230.590.640.73
EPS (Basic, Before Extraordinaries)0.340.04-0.18-0.160.210.250.590.650.49
EPS (Diluted)0.320.04-0.18-0.160.190.230.550.600.45
EBITDA46.3331.707.36-11.0412.5920.0882.3274.3048.66
Non-Operating Income (Expense)19.40-4.836.9022.2919.0217.49-16.651.10-0.52
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.5510.258.336.954.756.786.293.733.44
Price To Earnings Ratio38.9338.93--23.7935.9825.7822.99-
Price To Sales Ratio1.933.502.283.063.793.164.90--
Gross Margin82.7785.0584.3785.2389.2786.8986.9984.7780.81
Operating Margin8.845.55-1.23-8.981.805.5035.0835.7827.61
Net Margin6.220.76-3.98-4.306.658.0417.7921.4118.50
Shares Outstanding70.7870.1768.0367.1165.6364.8763.8863.1362.15
Market Capitalization935.69935.69682.76765.13718.54570.42970.69973.03-

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue117.4890.0872.71106.4296.8694.4579.1592.04
Cost of Goods Sold Incl. D&A18.1617.516.6724.297.079.128.3314.77
Gross Profit99.3272.5666.0482.1389.7985.3370.8277.28
Selling, General and Administrative Excl. Other71.6570.5663.5280.1373.9674.0870.4570.72
Research and Development29.5732.2625.6532.0823.2923.8119.0622.14
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income27.672.002.522.0015.8311.250.376.55
Interest Expense2.702.702.702.303.284.765.102.48
Unusual Expense0.202.107.830.000.202.137.810.20
Net Income Before Taxes31.102.44-4.383.9012.936.89-11.557.05
Income Taxes8.791.400.46-0.505.182.533.102.88
Consolidated Net Income22.381.60-5.235.307.474.66-14.903.67
Net Income From Continuing Operations22.381.60-5.235.307.474.66-14.733.67
Net Income22.381.60-5.235.307.474.66-14.733.67
EPS (Recurring)0.300.040.000.070.110.09-0.140.06
EPS (Basic, Before Extraordinaries)0.320.02-0.070.080.110.07-0.220.05
EPS (Diluted)0.300.02-0.070.070.110.07-0.220.05
EBITDA30.445.035.655.2018.5413.992.969.21
Non-Operating Income (Expense)6.335.253.634.200.582.530.993.18
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense1.322.482.403.342.372.611.911.95
Price To Earnings Ratio38.9378.08412.901,227.08----
Price To Sales Ratio1.933.043.153.552.742.151.782.31
Gross Margin84.5580.5690.8377.1892.7090.3489.4883.96
Operating Margin23.552.223.471.8816.3411.910.477.12
Net Margin19.051.77-7.204.987.714.94-18.613.99
Shares Outstanding70.7870.7870.1470.1768.5168.5168.0368.03
Market Capitalization935.69980.981,167.141,210.66993.46727.25569.16682.76

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments179.86167.89213.42207.56192.15205.4174.4291.8170.44
Short Term Receivables48.4450.1742.6225.3327.5931.7726.3318.2912.23
Inventories64.9055.7256.7642.3327.3121.0816.2419.7922.02
Other Current Assets6.264.653.542.292.394.002.562.071.29
Total Current Assets299.47278.44316.34277.50249.44262.26119.55131.97105.97
Net Property, Plant & Equipment23.9724.1333.4739.1433.1621.5716.319.609.89
Total Investments and Advances9.875.7411.9310.839.467.608.731.381.60
Intangible Assets135.5461.0471.2775.1283.8393.7479.4859.9468.00
Deferred Tax Assets41.5041.9237.8629.2127.0233.6134.7240.1011.34
Other Assets0.090.090.090.230.190.000.002.292.76
Total Assets510.44411.36470.96432.04403.12418.79258.80245.28199.56
Short Term Debt Incl. Current Port. of LT Debt8.717.195.445.234.303.9953.3640.5827.21
Accounts Payable8.5410.1016.028.757.6013.426.017.5911.32
Other Current Liabilities98.5456.5156.5145.7134.8759.1655.0046.2534.41
Total Current Liabilities115.7973.8077.9759.7046.7776.57114.3794.4272.94
Long Term Debt107.07105.12166.10161.46157.46157.384.9042.7971.51
Provision for Risks Charges0.000.000.000.000.000.210.230.000.00
Deferred Tax Liabilities10.4811.388.106.245.811.852.630.10-
Other Liabilities0.000.000.000.000.170.0019.1737.3835.77
Total Liabilities233.34190.30252.18227.40210.21236.02141.29174.69180.22
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity277.10221.06218.78204.64192.92182.77117.5070.5919.34
Total Shareholders Equity277.10221.06218.78204.64192.92182.77117.5070.5919.34
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity277.10221.06218.78204.64192.92182.77117.5070.5919.34
Total Liabilities & Stockholders Equity510.44411.36470.96432.04403.12418.79258.80245.28199.56
Book Value Per Share3.953.253.263.122.972.861.861.140.33
Tangible Book Value Per Share2.022.352.201.971.681.390.600.17-0.84
Full-Time Employees--------150
Price to Book Ratio3.213.023.573.593.015.316.09--
Return on Assets0.62-2.68-2.343.283.8911.1216.0713.26-51.61
Return on Equity1.15-5.37-4.996.888.5025.0843.0865.57-356.00
Return on Invested Capital0.74-3.62-2.743.744.5611.0733.1026.01-94.66
Quick Ratio2.033.023.333.944.753.150.901.191.15
Current Ratio2.593.774.064.655.333.431.051.401.45

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income34.3512.89-8.48-12.0315.0023.0443.9968.1744.82
Depreciation11.9610.7611.0211.0313.2019.588.295.794.64
Other Funds (Non Cash)5.6615.731.27-3.39-9.29-4.3332.92-11.36-8.70
Funds from Operations51.9739.383.81-4.3918.9038.2985.2062.6140.77
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-23.0810.42-10.04-16.77-0.66-5.42-4.213.60-6.18
Cash from Operating Activities28.8849.79-6.22-21.1618.2432.8881.0066.2034.58
Capital Expenditures-0.87-0.76-0.79-1.47-1.98-16.69-15.26-25.42-4.45
Net Assets From Acquisitions0.07-65.550.000.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments-84.4284.7532.36-149.437.30-4.58-0.33-2.800.00
Purchase of Investments-102.70-0.74-283.81-382.610.00-4.58-0.33-2.800.00
Sale Or Maturity of Investments18.2885.49316.17233.177.300.000.000.000.00
Other Uses-0.00-0.000.000.000.000.000.000.000.00
Other Sources0.000.000.0021.310.000.000.000.000.00
Cash from Investing Activities-85.2318.4331.56-129.595.33-21.27-15.59-28.22-4.45
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock10.9619.875.578.152.284.712.783.1112.38
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock10.9619.875.578.152.284.712.783.1112.38
Proceedsfrom Stock Options0.000.000.000.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.00-30.330.000.000.0082.76-35.15-20.52
Change in Long Term Debt0.000.00-30.330.000.000.00-0.000.00
Issuance of Long Term Debt0.000.00104.350.000.000.00-0.000.00
Reduction of Long Term Debt-0.00-134.690.000.000.00-0.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.00-24.96-20.67-19.740.00
Other Financing Activities Uses0.000.000.000.000.00-24.96-20.67-19.740.00
Cash from Financing Activities-5.8514.48-29.903.01-1.03-23.4662.68-53.98-8.14
Exchange Rate Effect0.217.93-2.202.13-7.39-1.82-14.401.513.39
Net Change in Cash-61.9890.64-6.77-145.6115.15-13.68113.69-14.4925.39
Free Cash Flow28.0149.04-7.01-22.6016.8722.1576.3563.5631.64
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow26.6326.91--46.2428.3013.59--
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments189.56158.28170.90179.86166.86128.73
Short Term Receivables74.8356.9860.0348.4443.6153.33
Inventories57.9965.4364.5864.9067.1463.72
Other Current Assets---6.26--
Total Current Assets322.38280.69295.51299.47277.60245.78
Net Property, Plant & Equipment19.5020.4823.1023.9724.9924.57
Total Investments and Advances9.959.809.019.878.698.72
Intangible Assets125.67128.08130.99135.54134.93135.90
Deferred Tax Assets19.0528.8430.6741.5027.4831.20
Other Assets0.090.090.090.090.100.10
Total Assets496.64467.98489.37510.44473.79446.26
Short Term Debt Incl. Current Port. of LT Debt9.079.058.148.719.699.56
Accounts Payable90.0782.32103.53105.9078.2278.38
Other Current Liabilities0.821.880.681.19-0.00-0.00
Total Current Liabilities99.9593.25112.35115.7987.9187.94
Long Term Debt105.45117.71108.06107.07121.23130.99
Provision for Risks Charges0.000.000.000.000.000.00
Deferred Tax Liabilities---10.48--
Other Liabilities0.000.000.000.000.000.00
Total Liabilities205.40210.95220.41233.34209.14218.93
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity291.24257.03268.96277.10264.64227.33
Total Shareholders Equity291.24257.03268.96277.10264.64227.33
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity291.24257.03268.96277.10264.64227.33
Total Liabilities & Stockholders Equity496.64467.98489.37510.44473.79446.26
Book Value Per Share4.113.633.833.953.863.32
Tangible Book Value Per Share2.341.821.972.021.891.33
Price to Book Ratio3.213.624.314.574.373.40
Return on Assets4.952.002.730.580.24-1.72
Return on Equity8.653.775.051.080.44-3.40
Return on Invested Capital5.640.43-1.391.381.931.30
Quick Ratio2.652.312.062.032.392.07
Current Ratio3.233.012.632.593.162.79

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income31.263.05-4.774.8012.837.05
Depreciation2.772.853.133.212.722.74
Other Funds (Non Cash)5.45-0.053.16-2.895.430.97
Funds from Operations39.485.851.515.1220.9810.76
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-6.93-18.540.112.279.031.66
Cash from Operating Activities32.55-12.681.637.3930.0112.42
Capital Expenditures-0.28-0.08-0.24-0.27-0.07-0.13
Net Assets From Acquisitions0.000.000.000.07-1.67-0.46
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments0.050.22-84.830.14-0.6117.71
Purchase of Investments0.050.27-103.02-0.01-0.30-0.02
Sale Or Maturity of Investments-0.01-0.0518.190.15-0.3117.73
Other Uses0.000.000.00-0.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.230.14-85.07-0.06-2.3417.12
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.601.213.895.2513.331.06
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.601.213.895.2513.331.06
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.00--
Issuance of Long Term Debt0.000.000.000.00--
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities-0.410.21-9.263.6011.95-0.31
Exchange Rate Effect-0.420.29-0.901.23-1.376.12
Net Change in Cash31.49-12.04-93.6012.1638.2535.34
Free Cash Flow32.27-12.771.397.1229.9412.29
Price to Free Cash Flow26.6343.2623.0027.1220.2725.79

Revenue breakdown

JOENJA2024: 44.96M 2025: 58.21M
RUCONEST2024: 252.24M 2025: 317.92M
Europe And Rest Of The World2024: 10.05M 2025: 14.39M
United States2024: 287.15M 2025: 361.75M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-30-0.0M-24.45K
2026-10-15-0.0M-22.79K
2026-09-30-0.0M-22.64K
2026-09-15-0.0M-14.67K
2026-08-31-0.0M-13.16K
2026-08-14-0.1M-12.50K
2026-07-31-0.0M-10.80K
2026-07-15-0.0M-10.02K
2026-06-30-0.0M-11.68K
2026-06-15-0.0M-15.49K
2026-05-29-0.0M-17.33K
2026-05-15-0.0M-18.56K
2026-04-30-0.0M-22.74K
2026-04-15-0.0M-27.16K
2026-03-31-0.0M-29.17K
2026-03-13-0.0M-29.09K
2026-02-27-0.0M-29.94K
2026-02-13-0.0M-28.92K
2026-01-30-0.0M-25.68K
2026-01-15-0.0M-21.97K

Option chain

expiry 2026-11-11
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
No option chain for this symbol.

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-11-06SEC
2026-10-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-27SEC
2026-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-22SEC
2026-10-146-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-10-14SEC
2026-09-296-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-29SEC
2026-09-256-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-25SEC
2026-09-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-22SEC
2026-09-116-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-09-11SEC
2026-08-136-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-08-13SEC
2026-07-306-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-07-30SEC
2026-06-046-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-06-04SEC
2026-05-286-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-28SEC
2026-05-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-22SEC
2026-05-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-07SEC
2026-05-076-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-05-07SEC
2026-04-166-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-16SEC
2026-04-1320-F/A2025-12-31SEC
2026-04-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-04-02SEC
2026-04-0220-FRegistration statement under Section 12 of the Securities Exchange Act of 1934 or an annual or transition report filed under Section 13(a) or 15(d) of the Exchange Act for a foreign private issuer.2025-12-31SEC
2026-03-276-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-27SEC
2026-03-246-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-24SEC
2026-03-126-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-03-12SEC
2026-02-036-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-03SEC
2026-02-026-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-02-01SEC
2026-01-086-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162026-01-08SEC
2025-11-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-11-06SEC
2025-10-226-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-20SEC
2025-10-066-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-06SEC
2025-10-016-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-10-01SEC
2025-09-106-KCurrent report of foreign issuer pursuant to Rules 13a-16 and 15d-162025-09-10SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
Silverberg Bernstein Capital Management LLC0.05%
Crossmark Global Holdings, Inc.0.02%
CITADEL ADVISORS LLC0.02%
MORGAN STANLEY0.02%
SmartHarvest Portfolios, LLC0.01%
Knoll Capital Management, LLC0.01%
Nalls Sherbakoff Group, LLC0.00%
Global Retirement Partners, LLC0.00%
Optiver Holding B.V.0.00%
BNP PARIBAS FINANCIAL MARKETS0.00%

Funds

Fund% owned
Old Westbury Small & Mid Cap Strategies Fund0.10%
Steward Values Enhanced International Fund0.02%
Fidelity Nasdaq Composite Index Fund0.00%

OakChart. PHAR. Cached 15 minutes.

Some panels did not load: insider.